Rationale Modulators of the ρ1 GABA A receptor may be useful in the treatment of visual, sleep, and cognitive disorders. Neuroactive steroids and analogues have been shown to modulate ρ1 receptor function, but the molecular mechanisms are poorly understood. Objectives We employed electrophysiology and voltageclamp fluorometry to compare the actions of several neuroactive steroids and analogues on the human ρ1 GABA A receptor.
Introduction
Ionotropic ρ1 GABA A receptors are homopentameric membrane proteins that belong to the Cys loop family of ligandgated ion channels. Binding of the neurotransmitter GABA leads to opening of a channel permeable to Cl − and other small anions. GABA A receptors containing the ρ subunit are predominantly expressed in the retina where knockout of the ρ1 subunit eliminates GABA-evoked responses in rod bipolar cells (McCall et al. 2002) . Additionally, ρ subunits are expressed in the hippocampus (Alakuijala et al. 2005; Didelon et al. 2002) , superior colliculus (Schlicker et al. 2009; Wahle and Schmidt 2009) , visual cortex (Wahle and Schmidt 2009) , cerebellum (Rozzo et al. 2002; Wegelius et al. 1998) , and dorsal root ganglia (Wegelius et al. 1998) . The physiological and pharmacological properties of ρ receptors differ in some aspects from the more common αβγ and αβδ subtypes of the GABA A receptor. Currents from ρ receptors are insensitive to bicuculline (Shimada et al. 1992; Wang et al. 1994) , have a slower deactivation rate (Amin and Weiss 1994) , and have a significantly lower (subpicosiemens) single-channel conductance (Pan et al. 1997; Wotring et al. 1999) . Similar to the extrasynaptic α4βδ receptors, ρ receptors are highly sensitive to GABA and demonstrate little desensitization (Amin and Weiss 1994; Lu and Huang 1998) . The ρ receptor is thus best suited to respond to ambient GABA and contribute to tonic inhibition (Alakuijala et al. 2006) . Drugs acting on the ρ1 GABA A receptor may be useful in the treatment of a variety of visual, sleep, and cognitive disorders (Johnston et al. 2003) . A recent study demonstrated that cis-and trans-(3-aminocyclopentanyl)methylphosphinic acid, selective antagonists of ρ receptors, can prevent the development of myopia (Chebib et al. 2009 ). The same study indicated that following intraperitoneal injection, ρ antagonists enhanced learning and memory in rats in the Morris water maze task. Furthermore, receptors containing the ρ subunit have been implicated in apoptosis of hippocampal neurons (Yang et al. 2003) and regulation of hormone release in the pituitary gland (Boue-Grabot et al. 2000) . 4, 5, 6, pyridin-3-ol (THIP), which is an agonist of the αβγ GABA A receptor but antagonist of the ρ subtype, induces analgesia in rodents and humans (Asiedu et al. 2012; Kjaer and Nielsen 1983) . It has been proposed that antagonism of the ρ receptor contributes to the analgesic effect of THIP (Johnston et al. 2003) .
Among the modulators of the ρ1 GABA A receptor are several neuroactive steroids, which, depending on their structure, can potentiate or inhibit currents elicited by GABA. Typically, 5α-reduced steroids, such as (3α,5α)-3-hydroxypregnan-20-one and (3α,5α)-3,21-dihydroxypregnan-20-one (5αTHDOC), potentiate the receptor whereas their 5β-reduced analogues (3α,5β)-3-hydroxypregnan-20-one (3α5βP) and (3α,5β)-3,21-dihydroxypregnan-20-one (5βTHDOC) have an inhibitory effect (Morris et al. 1999) . Sulfated steroids, regardless of the configuration at C5, and the sex hormone 17β-estradiol inhibit the ρ1 receptor (Li et al. 2007) .
Here, we have employed molecular biology, electrophysiology, and voltage-clamp fluorometry to examine modulation of the human ρ1 GABA A receptor by several steroids and analogues. The data indicate significant differences in the molecular mechanisms of action despite the common-inhibitory-functional effect and related structure. The P294S mutation (P2′S mutation in the second membrane-spanning domain) abolished potentiation by 3α5βP but had no effect on inhibition by (3α,5β)-3-hydroxypregnan-20-one sulfate (3α5βPS) or 17β-estradiol. When the receptors contained the T298F mutation (6′ residue in the M2), channel inhibition by 17β-estradiol, but not 3α5βP or 3α5βPS, was greatly reduced. Voltage-clamp fluorometry experiments indicated that 3α5βP, 3α5βPS, and 17β-estradiol differently affect structural changes taking place during activation by GABA in the extracellular domain.
Materials and methods

Molecular biology and expression
The experiments were conducted on wild-type and mutant human ρ1 (GenBank accession no. M62400) GABA A receptors expressed in Xenopus laevis oocytes. Two sites in the membrane-spanning domain were mutated to electrophysiologically examine the effects of these mutations on modulation by steroids. The substitutions were P294S and T298F (2′ and 6′ residues in the second membrane-spanning domain, respectively). For use in fluorometry experiments, four cysteine mutations were made in the extracellular domain. The sites were K217 (loop F), Y241 (loop C), L166 (Loop E) and S66 (subunit interface). A subset of these mutations were combined with the I307Q (second membrane-spanning domain) mutation.
The cDNAs were subcloned into the pGEMHE expression vector in the T7 orientation. The cDNAs were linearized by NheI (NEB Labs, Ipswich, MA) digestion, and the cRNAs were produced using mMessage mMachine (Ambion, Austin, TX). The oocytes were injected with 5-15 ng cRNA in a volume of 20-60 nl and incubated in ND96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 2.5 mM sodium pyruvate, and 5 mM HEPES; pH 7.4) at 16°C for 2-5 days before labeling and recording.
Electrophysiological and fluorescence recordings
Electrophysiological measurements were conducted using an RC-1Z (Warner Instruments) recording chamber. Currents were recorded using standard two-electrode voltage clamp. Both voltage and current electrodes were patch-clamp electrodes filled with 3 M KCl and had resistances of 0.5 to 1.5 M Ω. The oocytes were clamped at −60 mV. The chamber was perfused continuously at approximately 5 ml/min. Bath solution was perfused between test applications. Solutions were applied from glass reservoirs via metal or Teflon tubing to reduce adsorption and switched via pClamp using a Warner Instruments VC-8 T valve controller. The current responses were amplified with an Axoclamp 900A amplifier (Molecular Devices, Sunnyvale, CA), digitized with a Digidata 1320 series digitizer (Molecular Devices) at a 100-Hz sampling rate, and stored using pClamp (Molecular Devices).
Voltage-clamp fluorescence measurements were conducted using Alexa Fluor 546 C5 maleimide (A5m; Invitrogen, Carlsbad, CA) as the fluorescence reporter. Labeling with A5m was carried out by incubation for 45-60 min at room temperature in the dark with 20 μM A5m dissolved in OR2 (92.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl 2 , 10 mM HEPES) at pH 7.2. Following labeling, the oocytes were kept in bath solution (OR2, pH 7.5) before use in experiments.
For fluorescence recordings, we employed a custom-made recording chamber (Akk and Steinbach 2011; Chang and Weiss 2002) . The chamber consists of two compartments, separated by a 0.8-mm aperture on which the oocyte is placed. The oocyte is impaled in the top compartment which contains static bath. Part of the surface of the oocyte is exposed via the aperture to the lower compartment. The drugs (agonist and modulators) are added to the bath flowing through the lower compartment. The seal between the oocyte and the aperture is tight and there is little leakage between the two compartments. Accordingly, the fluorescence and peak current signals are measured from the same general population of receptors.
An inverted microscope (Nikon Diaphot TMD) fitted with a Nikon 20X LWD 0.4 NA objective was used to collect the fluorescence signal from the lower chamber. The microscope holds dichroic (565DCLP) and emission (D605/55 m) filters (Chroma Technology Corp, Rockingham, VT) for fluorescence detection. The fluorescence measurement system was purchased from Photon Technology International (Birmingham, NJ). The system consists of a DeltaRAM monochromator, a liquid light guide that is used to pass the light (546 nm) into the microscope, a photomultiplier tube (R1527P Hamamatsu Photonics, Bridgewater, NJ) mounted on the side port of the microscope, BryteBox acquisition hardware, and FeliX32 software for control of excitation. A 75-W xenon short-arc lamp (Ushio Inc., Tokyo, Japan) was employed as the light source.
Experiments and analyses
The functional effect of each steroid was determined as follows. A cell was initially exposed to a saturating concentration of GABA, followed by a washout. Several applications were then made with low (EC 5-10 ) GABA, until a stable response was obtained. This was followed by an application of low GABA+steroid. Another exposure to low GABA was conducted to verify reversibility of the effect of steroid. Control experiments were conducted to test direct activation by steroids. Drug applications lasted 20-40 s, followed by 1-3-min washouts. Previous work has revealed that steroid IC 50 values are in the low micromolar range (Li et al. 2007 ). To reduce error arising from cell to cell variability and to focus on maximal effects, all experiments were conducted employing 20 μM steroid.
Fluorescence changes were measured on oocytes labeled with Alexa 546 maleimide (A5m). The sequence of drug applications was similar to the one described above. The effects of steroids, however, were examined in the presence of higher concentrations of GABA ). Higher concentrations of GABA were necessary in this set of experiments to reliably elicit a robust fluorescence response. The use of higher concentrations of GABA resulted in a smaller magnitude of functional effect of steroid. We also tested the effect of steroid in the absence of GABA. In each case, the application of steroid alone was without effect on current or fluorescence signal.
Current and fluorescent transients were analyzed with Clampfit (Molecular Devices). Fluorescence baseline was corrected for bleaching when needed. The magnitude of the current response was estimated as the peak response within the window of drug application. The magnitude of the fluorescence signal was estimated as the mean response within the saturated portion of the fluorescence response (Fig. 1) . The parameter measured is the "response ratio," i.e., the ratio of the response to GABA+steroid to the response to GABA prior to steroid exposure. Statistical analyses were carried out using paired t test (Excel, Microsoft, Richmond, WA).
Drugs
The salts used in the study were purchased from SigmaAldrich (St. Louis, MO). The steroid analogues (3α,5β)-3-hydroxymethylpregnan-20-one (S84-1) and (3α,5β,17β)-3-hydroxyandrostane-17-carbonitrile (B164) were prepared by us (Han et al. 1996; Jin et al. 2009 ). Remaining steroids were purchased from Sigma-Aldrich (St. Louis, MO) or Steraloids (Newport, RI). Stock solutions (20 mM) of the steroids were made in dimethyl sulfoxide (DMSO); dilutions to test concentrations were made on the day of the experiment. Stock solution of A5m was made in DMSO at 5 mM and stored in aliquots at −80°C. The structures of steroids used are given in Figs. 3a and 6a.
Results
Mutations to the membrane-spanning domain differently affect the actions of inhibitory steroids Human ρ subunit-containing GABA A receptors are susceptible to modulation by steroids. In particular, the ρ1 receptor is inhibited by 5β-reduced steroids, charged (sulfated or carboxylated) steroids, and the sex hormone 17β-estradiol (Li et al. 2007; Morris et al. 1999 ). Our data demonstrate that wild-type ρ1 receptors expressed in Xenopus oocytes exhibit strong inhibition of peak responses in the presence of 3α5βP, 3α5βPS, or 17β-estradiol. The peak responses from wildtype receptors activated by 0.15 μM GABA (EC 5 ) were reduced to 40±8 % (mean±SD) of control (four cells; p < 0.001, paired t test) in the presence of 20 μM 3α5βP. Application of 20 μM 3α5βPS reduced the peak response to 26±5 % of control (four cells; p <0.001). When 20 μM 17β-estradiol was coapplied with GABA, the peak response was reduced to 38±13 % of control (four cells; p <0.01). Sample recordings are shown in Fig. 2a .
Introduction of the P-to-S mutation at position 294 (2′ in the second membrane-spanning domain) affected modulation by steroids. Coapplication of 20 μM 3α5βP with 0.75 μM GABA (EC 7 ) was without effect on the peak amplitude (85±10 % of control, four cells; p >0.05). The mutant receptors were inhibited by 20 μM 3α5βPS (30±4 % of control, four cells; p <0.001) or 20 μM 17β-estradiol (59±7 % of control, four cells; p <0.01). Thus, the P294S mutation enables distinction between the inhibitory effects of 3α5βP vs. 3α5βPS and 17β-estradiol. The simplest explanation is that the sites and/or mechanisms of action of 3α5βP differ from those of 3α5βPS and 17β-estradiol. Sample current traces are shown in Fig. 2b .
We next tested the effect of the T-to-F mutation at position 298 (6′ in the second membrane-spanning domain). There was no effect on peak responses when 20 μM 17β-estradiol was coapplied with 0.15 μM GABA (EC 5 ) (100±6 % of control, four cells; p >0.05). Coapplication of 20 μM 3α5βPS with GABA reduced the peak amplitude of the mutant receptors to 20±6 % of control (four cells; p <0.001). Interestingly, in the presence of 20 μM 3α5βP, the peak amplitude was enhanced to 217±94 % of control (five cells; p <0.05). Sample recordings are shown in Fig. 2c .
The effects of steroids were also tested on ρ1(T298F) mutant receptors in the presence of 0.3 μM GABA (EC [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] ). The average peak response elicited by 0.3 μM GABA was reduced to 52±15 % of control (four cells; p <0.01) or 17±2 % of control (four cells; p <0.001) in the presence of 3α5βP or 3α5βPS, respectively. Thus, the polarity of the effect of T298F on modulation by 3α5βP is dependent on the concentration of GABA used to activate the receptor. The mean peak response in the presence of 20 μM 17β-estradiol was 102±2 % of control (four cells; p >0.05). Sample traces are shown in Fig. 2d . A summary of the findings is presented in Fig. 2e .
To probe direct activation by steroids, oocytes expressing ρ1(P294S) or ρ1(T298F) receptors were exposed to 20 μM 3α5βP, 3α5βPS, or 17β-estradiol. In one case (ρ1(P294S)), exposure to 3α5βP resulted in inward current that had a mean peak response of 0.05±0.03 % (five cells) of the peak response to saturating GABA. In all other steroid-receptor combinations, exposure to steroid led to apparent outward current that we interpret as steroid-induced closure or block of spontaneously active receptors. We note that these data exclude the possibility that enhancement of currents from ρ1(T298F) receptors activated by a low concentration of GABA in the presence of 3α5βP (Fig. 2c ) is due to receptors being directly activated by the steroid.
In sum, the P294S and T298F mutations selectively affect inhibition of the human GABA A ρ1 receptor by 3α5βP, 3α5βPS, and 17β-estradiol. The P294S mutation, by eliminating inhibition by 3α5βP, distinguishes the actions of 3α5βP from those of 3α5βPS and 17β-estradiol. The T298F mutation removes inhibition by 17β-estradiol, therefore differentiating the actions of 17β-estradiol from 3α5βP and 3α5βPS. We infer that the three steroids act via distinct sites and/or mechanisms. The left traces show raw data, while the right traces show the data after filtering (9 Hz) and baseline correction (blue dashed lines in left traces). The oocyte was exposed to bath solution for 10 s, followed by a 30-s pulse of 30 mM GABA (a saturating concentration) and a 40-s washout period. The current response was determined as the peak response within window 1. In cases where there was no clear peak or the signal-to-noise ratio was low, the current response was determined as the mean current within a window covering a portion of the trace with no apparent change in amplitude. The fluorescence change (ΔF) was determined as the ratio of signal (mean amplitude within window 3) to baseline (mean amplitude within window 2) and is expressed in percent Inhibitory steroids elicit distinct conformational changes in the extracellular domain Voltage-clamp fluorometry (VCF) entails the measurement of the fluorescence signal from a fluorophore linked to an introduced cysteine residue (Mannuzzu et al. 1996) . A change in fluorescence signal (ΔF) in the presence of a drug is widely accepted as an indication of a structural rearrangement leading to altered polarity of the environment surrounding the fluorophore. This approach is particularly useful in comparing and contrasting the effects of drugs. Here, we have investigated the effects of the steroids 3α5βP, 3α5βPS, and 17β-estradiol (structures in Fig. 3a) on GABA-induced ΔF, to determine whether inhibition of channel function is associated with changes in GABA-elicited structural rearrangements.
We selected four residues in the extracellular domain for labeling. The residues were K217 (within loop F, contributes to the transmitter binding site), S66 (at the subunit-subunit interface, outside of the transmitter binding pocket), L166 (loop E, top of the transmitter binding site), and Y241 (loop C, critically important for activation). The selected residues were mutated to cysteine and labeled with Alexa 546 maleimide. Previous work has demonstrated that these sites respond with a robust fluorescence change to receptor activation by GABA (Chang and Weiss 2002; Khatri et al. 2009 ).
Inhibition of ρ receptors by steroids is pseudocompetitive, i.e., the inhibitory effect is reduced at higher concentrations of the agonist (Li et al. 2007 ). Accordingly, steroid effects were examined at submaximal GABA concentrations while maintaining constant fractional activation (EC 39-72 across the various mutants). Coapplication of 3α5βP, 3α5βPS, or 17β-estradiol with GABA reduced electrophysiological responses from labeled mutant receptors (Fig. 3b-e) . Peak responses during exposure to steroid ranged from 27±7 % (K217C in the presence of 17β-estradiol) to 79±14 % (Y241C in the presence of 3α5βPS) of the response to GABA alone. A summary is given in Fig. 3f .
Steroid effects on fluorescence varied. In the K217C receptor, coapplication of 20 μM 3α5βPS with GABA reduced the ΔF to 75±12 % (p <0.05) of that observed in the presence of GABA alone. In contrast, exposure to 3α5βP or 17β-estradiol was without effect on ΔF (Fig. 3b, f) . Thus, at the K217C site, modulation of the fluorescence signal distinguishes the actions Fig. 2 Effects of P294S and T298F mutations on human ρ1 receptor modulation by 3α5βP, 3α5βPS, and 17β-estradiol. a Sample current responses from wild-type ρ1 receptors activated by 0.15 μM GABA (<EC 10 ) in the absence and presence of 20 μM 3α5βP, 3α5βPS, or 17β-estradiol. The peak response is inhibited in the presence of steroids. b Sample current responses from ρ1 receptors containing the P294S (2′ in the second membrane-spanning domain) mutation activated by 0.75 μM GABA (<EC 10 ) in the absence and presence of 20 μM 3α5βP, 3α5βPS, or 17β-estradiol. The peak response is inhibited in the presence of 3α5βPS or 17β-estradiol, but not 3α5βP. c Sample current responses from ρ1 receptors containing the T298F (6′ in the second membrane-spanning domain) mutation activated by 0.10-0.15 μM GABA (<EC 10 ) in the absence and presence of 20 μM 3α5βP, 3α5βPS, or 17β-estradiol. The peak response is enhanced by 3α5βP and inhibited by 3α5βPS. The application of 17β-estradiol has no effect on the peak current. d Sample current responses from ρ1 receptors containing the T298F mutation activated by 0.3 μM GABA (EC [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] ) in the absence and presence of 20 μM 3α5βP, 3α5βPS, or 17β-estradiol. The peak response is inhibited in the presence of 3α5βP or 3α5βPS, but not 17β-estradiol. e Summary of the findings. The data show the effects of 20 μM 3α5βP (P), 3α5βPS (PS), or 17β-estradiol (17β-E2) on responses elicited by GABA alone. Data show mean±SD from four to five cells. The dotted line denotes no effect. Statistical analysis was done with paired t test (Excel, Microsoft, Redmond, WA) and applies to comparison to no effect. *p <0.05; **p <0.01; ***p <0.001; ns not significant of the sulfated steroid 3α5βPS from those of 3α5βP and 17β-estradiol.
Fluorescence changes in receptors labeled at the S66C site were inhibited by 3α5βPS and 17β-estradiol but not affected by 3α5βP (Fig. 3c, f) . The mean ΔF was reduced to 60±13 % of control (p <0.01) or 38±11 % of control (p <0.01) in the presence of 20 μM 3α5βPS or 17β-estradiol, respectively. In the presence of 3α5βP, the mean ΔF was 119±27 % of control. We infer that comparison of steroid effects on ΔF at the S66C site enables separation of the effects of 3α5βPS and 17β-estradiol from 3α5βP.
Receptors labeled at the L166C site exhibited sensitivity to 17β-estradiol, but not 3α5βP or 3α5βPS (Fig. 3d, f) . Application of 17β-estradiol reduced the mean ΔF to 54± 18 % of control (p <0.01). The effects by 3α5βP and 3α5βPS were not statistically different from no effect. Therefore, we conclude that L166C differentiates the effects of 17β-estradiol from the effects exerted by 3α5βP and its sulfated analogue, 3α5βPS.
Finally, all three steroids functionally inhibited receptors labeled at the Y241C site, but none modulated ΔF (Fig. 3e, f) . absence and presence of 20 μM 3α5βP (P), 3α5βPS (PS), or 17β-estradiol (17β-E2). In each case, the application of steroids reduced the peak amplitude of GABA-elicited current response. Drug-induced effects on fluorescence are shown with dotted lines. The traces are reproduced with permission from an earlier publication (Li et al. 2010) . f Summary of the effects of steroids. The data show the effects of 20 μM 3α5βP (P), 3α5βPS (PS ), or 17β-estradiol (17 β-E2 ) on responses elicited by GABA alone. Data show mean±SD from three to six cells. Unfilled columns show the effects of steroids on the peak current response. Shaded columns show the effects of steroids on fluorescence change. The dotted line denotes no effect. Statistical analysis was done with paired t test (Excel, Microsoft, Redmond, WA) and applies to comparison to no effect. *p <0.05; **p <0.01; ***p <0.001; ns not significant
Overall, the data demonstrate that the actions of inhibitory steroids are associated with structural rearrangements in the extracellular domain of the ρ1 receptor and that movements in the presence of 3α5βP, 3α5βPS, and 17β-estradiol involve different regions within the extracellular domain.
Are the structural changes in the extracellular domain productively or casually linked to functional modulation?
We next sought to determine whether steroid-elicited structural rearrangements in the extracellular domain are linked to the functional effects of the steroid or reflect associated, but nonproductive, rearrangements. In other words, are the conformational changes causal or casual?
An earlier study had found that the I307Q mutation reverses inhibition of the human ρ1 GABA A receptor by several 5β-reduced steroids (Morris and Amin 2004) . We examined the effect of the I307Q mutation on fluorescence changes in the presence of the same three classes of steroids. We reasoned that if the changes in ΔF result from the functional effect of the steroid, i.e., electrophysiological inhibition, then the presence of the mutation that reverses inhibition would also affect steroid-induced changes in ΔF. Conversely, if ΔF is associated with steroid binding per se, then the introduction of the I307Q mutation should not alter the ΔF signal. This interpretation is dependent on an assumption that introduction of the I307Q mutation solely alters the modulatory effect of a steroid without eliminating the original binding site for the steroid or introducing or unmasking a new site.
In initial experiments, we probed the effect of the I307Q mutation, alone and in the presence of the labeling mutation, on modulation of current responses by 3α5βP, 3α5βPS, and 17β-estradiol. Each steroid was coapplied at 20 μM along with GABA at a concentration eliciting 5-10 % of the maximal response. Our findings confirm that the I307Q mutation converts 3α5βP from being an inhibitor to being a potentiator (Fig. 4) . This effect was observed in the absence and presence of a labeling mutation (K217C, S66C, or Y241C); however, the I307Q mutation did not reverse the inhibitory effects of 3α5βPS or 17β-estradiol (Fig. 4) . These data provide further support to the hypothesis that inhibitory steroids act through different mechanisms on the ρ1 GABA A receptor. Control experiments conducted in the presence of steroid alone demonstrated that direct activation by steroids does not result in significant current responses (data not shown).
We next tested the effects of steroids on current and fluorescence responses from double mutant receptors labeled with A5m. To obtain a reliable fluorescence signal, the experiments were conducted at GABA concentrations eliciting an approximately half-maximal response (EC 47±15 , a total of 46 cells).
Currents from the ρ1(I307Q+K217C) receptor activated by GABA were potentiated by 20 μM 3α5βP (Fig. 5a ). The average peak response was 124±10 % of control (five cells; p <0.05). The increase in current was not accompanied by changes in ΔF. Thus, receptors labeled at the K217C site exhibit no changes in ΔF, regardless of whether the action of 3α5βP is potentiating (in the presence of I307Q; Fig. 5a ) or inhibitory (in the absence of I307Q; Fig. 3b ). Due to the higher GABA concentration used, potentiation of peak current response was less in fluorescence experiments compared to data shown in Fig. 4 .
The actions of 3α5βPS and 17β-estradiol were inhibitory on the ρ1(I307Q+K217C) receptor, i.e., the presence of the I307Q mutation did not convert these steroids into potentiators. The I307Q mutation also did not affect how these steroids influenced ΔF; the application of 3α5βPS reduced the magnitude of ΔF (70±9 % of control, six cells; p <0.02) while 17β-estradiol was without effect on ΔF (106±3 % of control, three cells). The data are summarized in Fig. 5c .
In sum, the pattern of steroid-elicited effects on ΔF in ρ1(I307Q+K217C) is identical to that in the K217C mutant. Most importantly, the reversal of inhibition caused by the introduction of the I307Q mutation did not result in changes in ΔF in the presence of 3α5βP. We interpret this as the loop F Fig. 4 The effect of the I307Q mutation on modulation by 3α5βP, 3α5βPS, and 17β-estradiol. The graph shows the effects of 20 μM 3α5βP, 3α5βPS, or 17β-estradiol on peak currents elicited by GABA. GABA concentrations were selected to produce 5-10 % of the maximal response (EC 5-10 ). Data show mean±SD from three to five cells. The dotted line denotes no effect. Statistical tests (paired t test) apply to comparison to no effect. *p <0.05; **p <0.01; ***p <0.001. The data indicate that the I307Q mutation, regardless of the presence of a secondary Cys mutation used for labeling, reverses the inhibitory effect of 3α5βP, but does not reverse inhibition by 3α5βPS or 17β-estradiol. No statistical analysis was conducted to compare the effects of steroids among mutations due to small differences in the fractional responses to GABA and uncertainty about the maximal open probability for the mutants. Some receptor-steroid combinations consistently exhibited apparent outward currents when exposed to GABA+steroid, indicative of the presence of spontaneous activity that was inhibited when a steroid was coapplied with GABA. These cases are marked with number sign and were not subjected to statistical analysis residue reporting conformational changes that are not associated with or affected by the functional effect of 3α5βP.
Fluorescence changes at the Y241C site were dependent on the presence of the I307Q mutation. In receptors containing the I307Q mutation, the application of 3α5βP potentiated the peak response (130±7 % of control, seven cells; p <0.01) and enhanced ΔF (161±18 % of control; p <0.05). This finding is suggestive of the Y241C site "sensing" potentiation-related structural rearrangements. The sulfated steroid 3α5βPS inhibited the peak response (82±3 %, nine cells; p <0.001) but was without effect on ΔF (103±7 % of control). This behavior is similar to that observed in the absence of the I307Q mutation. Lack of effect of the I307Q mutation on peak response by 3α5βPS limits the interpretation. At minimum, the data indicate that sulfated steroids and 5β-reduced steroids act via different mechanisms. Finally, 17β-estradiol reduced the magnitude of ΔF (75±5 % of control, six cells; p <0.01) but was without effect on the current response (108±6 %; p >0.3). Sample traces are shown in Fig. 5b , and a summary is given in Fig. 5c . We believe that lack of inhibition of the peak response was due to a higher GABA concentration used in these experiments, because we had earlier found (Fig. 4) that coapplication of 17β-estradiol with EC 5-10 GABA results in inhibition. Reduction in ΔF suggests that 17β-estradiol modulates the conformational change at the Y241C site.
Additional members of the three groups of steroids
Electrophysiological and fluorescence data suggest that 3α5βP, 3α5βPS, and 17β-estradiol act on the ρ1 GABA A receptor via distinct mechanisms. Further studies demonstrated that structurally related steroids or other inhibitory compounds act similarly to the prototypic representatives. For example, the P294S mutation abolishes inhibition of the peak response by 5βTHDOC and (3α,5β,17β)-3-hydroxyandrostane-17-carbonitrile (B164), in addition to 3α5βP (Li et al. 2007 ). The P294S mutation does not affect modulation by 3α5βPS or other charged steroids such as (3α,5α)-3-hydroxypregnan-20-one sulfate (3α5αPS) and (3α,5β)-20-oxopregnane-3-carboxylic acid (3αCOOH5βP), suggesting that charged steroids act via similar mechanisms (Li et al. 2010; Li et al. 2007 ). Interestingly, the ρ1(T298F) mutation abolishes inhibition by 17β-estradiol and picrotoxinin, placing these two compounds into a common class of inhibitors. The ρ1(T298F) mutation did not affect inhibition by 5β-reduced steroids (3α5βP, 5βTHDOC, or B164) or charged steroids (3α5βPS, 3α5αPS, or 3αCOOH5βP).
Mutagenesis-based classification is generally maintained in voltage-clamp fluorescence. For example, ΔF at the K217C site is reduced by the sulfated steroids 3α5βPS and 3α5αPS, but not by 5β-reduced steroids (3α5βP, 5βTHDOC) or 17β-estradiol or picrotoxinin (Li et al. 2010) . Receptors labeled at Unfilled columns show the effects of steroids on the peak current response. Shaded columns show the effects of steroids on fluorescence change. The dotted line denotes no effect. Statistical analysis was done with paired t test (Excel, Microsoft, Redmond, WA) and applies to comparison to no effect. *p <0.05; **p <0.01; ns not significant the S66C site exhibit ΔF that is reduced by the sulfated steroids, and 17β-estradiol and picrotoxinin (Li et al. 2010) .
Fluorescence experiments have also revealed several cases where steroids closely related in structure induce distinct conformational rearrangements. In ρ1(I307Q+Y241C) receptors, 3α5βP enhances ΔF (161 % of control) while 5βTHDOC is without effect (107±8 % of control, six cells; p >0.4). The classic explanation is that potentiation by 3α5βP alters the nature of the conformational change in the vicinity of the Y241C site whereas potentiation by 5βTHDOC does not. The two steroids differ in their C17 (D ring) substituents, where 3α5βP has a methylketone group (acetyl) and 5βTHDOC has an α-hydroxymethylketone group. To further explore the relationship between steroid structure and conformational changes at the Y241C site, we examined the effects of the steroids etiocholanolone and B164 on ΔF. Etiocholanolone contains a ketone group on C17 whereas B164 has a carbonitrile. Structures of the compounds are shown in Fig. 6a . We found that although both etiocholanolone and B164 potentiate the functional responses, ΔF is not affected. For etiocholanolone, the current response was potentiated to 123±5 % of control (three cells; p <0.05) while ΔF was 104±6 % of control (p >0.6). When B164 was coapplied with GABA, the current response was 124±6 % of control (four cells; p <0.04), but the effect on ΔF (119±15 % of control; p >0.25) was not significant. The data are summarized in Fig. 6b .
We tested the effect of (3α,5β)-3-hydroxymethylpregnan-20-one (S84-1) as a positive control. This steroid analogue is similar to 3α5βP in structure except for the hydroxymethyl group on C3, instead of a hydroxy group (Fig. 6a) . We hypothesized that since both S84-1 and 3α5βP have a methylketone group on C17, S84-1 would also enhance ΔF. Indeed, we observed that ΔF increased to 149±10 % of control (four cells; p <0.02). Also as expected, the presence of S84-1 enhanced the peak current response (136±8 % of control; p <0.02; Fig. 6b ).
Discussion
The ρ1 GABA A receptor is modulated by a wide range of steroids and analogues. A general rule is that 5α-reduced steroids potentiate currents from ρ1 receptors whereas 5β-reduced steroids, charged steroids, and the steroid hormone 17β-estradiol inhibit the receptor (Li et al. 2007; Morris et al. 1999) . In this study, we have focused on the actions of inhibitory steroids on the human ρ1 GABA A receptor.
Comparison of the effects of P294S and T298F mutations (2′ and 6′ residues in the second membrane-spanning domain, respectively) has enabled division of inhibitory steroids into three classes: 5β-reduced steroids, charged (sulfated or carboxylated) steroids, and a separate class that includes 17β-estradiol and another GABA A receptor modulator, picrotoxinin. By voltage-clamp fluorometry, we have shown that representatives of the three classes of steroids elicit a distinct pattern of conformational changes in the extracellular domain of the ρ1 GABA A receptor. Classification of the compounds is generally similar using the two approaches.
Mutations made in the second membrane-spanning domain distinctively influence the actions of inhibitory steroids. The P294S and T298F mutations reveal different molecular mechanisms involved in inhibition, separating 3α5βP, 3α5βPS, and 17β-estradiol into different classes of inhibitory steroids. The P294S mutation eliminates inhibition by 3α5βP, thereby selectively affecting modulation by a 5β-reduced steroid but not charged steroids or 17β-estradiol.
The T298F mutation abolishes inhibition by 17β-estradiol, identifying a mechanism for 17β-estradiol that is distinct from those of charged steroids and 5β-reduced steroids. Interestingly, the effect of this mutation on modulation by 3α5βP depended on the concentration of GABA. It has previously been reported that inhibition by 3α5βP is not affected in the T298F mutant (Li et al. 2007 ). We could replicate this finding but only when a relatively high concentration (EC 40-50 ) of GABA was used to activate the receptor. Fig. 6 Summary of the effects of steroids on currents and fluorescence from ρ1(I307Q+Y241C) receptors. a Structures of the steroids (3α,5β)-3,21-dihydroxypregnan-20-one (5 βTHDOC ), (3α,5β,17β)-3-hydroxyandrostane-17-carbonitrile (B164), etiocholanolone (Etio), and (3α,5β)-3-hydroxymethylpregnan-20-one (S84 -1 ). The structure of 3α5βP is given in Fig. 3a. b Summary of the effects of steroids on currents and fluorescence changes in ρ1(I307Q+Y241C) receptors. Data show mean±SD from three to six cells. Unfilled columns show the effect of 20 μM 3α5βP, 5βTHDOC, B164, Etio, or S84-1 on the peak current response. Shaded columns show the effects of steroids on fluorescence change. The dotted line denotes no effect. Statistical tests (paired t test) apply to comparison to no effect. *p <0.05; ns not significant We found that 3α5βP enhanced currents elicited by EC 5-10 GABA. The mechanism of apparent potentiation of currents is unclear, but does not involve direct activation of the mutant receptor by steroids. It is possible that besides the inhibitory effect that dominates at higher concentrations of GABA, 3α5βP additionally potentiates monoliganded ρ1(T298F) receptors and that such potentiation successfully compensates for the inhibitory effect of steroid.
Block by 17β-estradiol is removed when the T298F mutation is present, regardless of GABA concentration. Inhibition by 3α5βPS is also not affected by GABA concentration. Despite the disparity, it is intriguing, and potentially useful, that the T298F mutation provides distinction between all three classes of inhibitory steroids at low GABA concentrations.
To explore whether inhibition of the current response is associated with structural changes in the extracellular domain, we employed voltage-clamp fluorometry. Sites previously shown to exhibit robust fluorescence changes during activation were selected for labeling by Alexa 546 maleimide. First and foremost, the data indicate that coapplication of steroids with GABA can modulate the magnitude of ΔF, indicating that steroid interactions with the receptor modify GABAelicited conformational changes in the extracellular domain. Steroids applied alone were without effect on ΔF. The location of the steroid binding site(s) in the ρ1 receptor is unknown but, by analogy to the α1β2γ2 GABA A receptor (Hosie et al. 2006) , is likely to be within the membranespanning domain. If so, the distance to which steroidinduced modification of conformation is transmitted is remarkable.
The data do not support a notion that inhibitory steroids act on the ρ1 receptor as classic open channel blockers. The pore blocking mechanism can be expected to be without effect on ΔF produced in the extracellular domain. Previous work has shown that competitive inhibitors can elicit ΔF at positions near the transmitter binding site (Chang and Weiss 2002; Khatri et al. 2009; Muroi et al. 2006) . The lack of effect of inhibitory steroids on ΔF when applied in the absence of GABA suggests that these steroids do not act as competitive antagonists of the ρ1 receptor. We propose that inhibitory steroids act through an allosteric mechanism.
The data indicate that inhibitory steroids act through different molecular mechanisms. We define a common molecular mechanism as one where compounds bind to the same docking site and cause indistinguishable conformational changes. The finding that distinct patterns of effects on ΔF emerge in the presence of different steroids indicates that the conformational changes are dissimilar. Specifically, we have shown that 3α5βPS, but not 3α5βP or 17β-estradiol, diminish ΔF produced by GABA at the K217C position. When the L166C residue was labeled, 17β-estradiol but not 3α5βP or 3α5βPS reduced ΔF. At the S66C position, exposure to 3α5βPS or 17β-estradiol reduced ΔF while 3α5βP was without effect. None of the drugs tested influenced ΔF at position Y241C.
A change in fluorescence is interpreted as a conformational change in the vicinity of the fluorophore; however, further interpretation is limited. A change in fluorescence signal contains no information about the physical direction or the extent of the conformational change. Fluorescence intensity is dependent on the polarity of the environment surrounding the fluorophore, and so the direction of ΔF is indicative of whether the environment has become more (reduction in F) or less (increase of the magnitude of F) polar. It is possible, however, for two ligands to induce different conformational changes yet show comparable fluorescence signals if the final microenvironment around the fluorophore is similar. Likewise, modification of ΔF in the presence of steroid only provides an indication that the GABA-elicited conformational change has been altered, without providing additional data on the character of the alteration. Nonetheless, this approach is highly valuable when comparing the effects of related drugs or conformational changes at homologous sites in different subunits.
To determine whether steroid-induced modifications are linked to the functional effect of a steroid, we examined the effect of the I307Q mutation on the pattern of fluorescence changes in ρ1 receptors. This mutation is known to reverse inhibition of the ρ1 receptor by several 5β-reduced neurosteroids (Morris and Amin 2004) . We reasoned that if the ΔF is associated solely with steroid binding, then the presence of the I307Q mutation would not alter the ΔF signal. Conversely, if the ΔF is associated with the functional effect of a steroid, then, for steroids whose actions are converted from inhibitory to potentiating, the presence of the I307Q mutation may lead to changes in the properties (magnitude or direction) of the ΔF signal. In practice, a positive result would have been a case where a steroid increases or decreases the ΔF in the absence of I307Q and has an opposite effect (a decrease or increase, respectively) in the presence of the I307Q mutation. Alternatively, an instance where an absence of change in ΔF is converted to a change in ΔF (or vice versa) following introduction of the I307Q mutation would also indicate a positive result.
We began by examining the functional effects of several steroids on ρ1 receptors. Our data confirm that introduction of the I307Q mutation reverses inhibition by 3α5βP and further show that the mutation similarly modifies the effect of several other 5β-reduced non-sulfated steroids. The I307Q mutation, however, did not reverse inhibition by the sulfated steroid 3α5βPS or by the steroid hormone 17β-estradiol. This finding corroborates the hypothesis that these steroids act via distinct mechanisms on the ρ1 GABA A receptor, but it may have limitations on how to interpret the data with respect to the causality of changes in ΔF.
Two sites (K217C and Y241C) were labeled and examined with respect to ΔF in the presence of the I307Q mutation.
Introduction of the I307Q mutation reversed inhibition of K217C by 3α5βP, but that did not lead to changes in ΔF. We infer that ΔF from K217C does not report the functional effect of 3α5βP. The application of 3α5βPS inhibited currents and ΔF from both K217C and ρ1(I307Q+K217C) mutant receptors. Thus, the data do not exclude the possibility that K217C reports structural changes associated with inhibition by sulfated steroids. The application of 17β-estradiol reduced peak current but was ineffective at altering ΔF, indicating that inhibition by 17β-estradiol does not lead to structural changes at the K217C site.
The data obtained from receptors labeled at the Y241C site were more complex. None of the steroids tested had affected ΔF from a receptor containing just the Y241C mutation, i.e., inhibition by 3α5βP, 3α5βPS, or 17β-estradiol did not affect GABA-elicited structural changes. With the addition of the I307Q mutation, 3α5βP and 5βTHDOC were rendered potentiating whereas 3α5βP, but not 5βTHDOC, also enhanced the ΔF. This suggests that potentiation by 3α5βP, but not 5βTHDOC, affects the structural change at the Y241C site. The structures of the two steroids differ in their C17 substituents (methylketone in 3α5βP and α-hydroxymethylketone in 5βTHDOC). Further investigations revealed that steroids with a ketone (etiocholanolone) or carbonitrile (B164) group at C17 did not modify ΔF in the ρ1(I307Q+Y241C) receptor, indicating that, of the steroids studied, 3α5βP uniquely modifies conformational changes at the Y241C site. The steroid analogue S84-1 was then tested because of its similarity to 3α5βP at C17 (methylketone). This compound, like 3α5βP, enhanced ΔF from the ρ1(I307Q + Y241C) receptor, supporting the idea that the nature of the C17 substituent defines the effect at the Y241C site. Overall, these data suggest that the labeled Y241C residue reports productive conformational changes, i.e., conformational changes associated with the functional effect of a steroid, for 5β-reduced steroids containing a methylketone group at position C17 (3α5βP and S84-1).
The underlying assumption in our interpretations is that the I307Q substitution does not generate or unmask a novel steroid interaction site. Rather, it alters the type of effect exerted by a 5β-reduced non-sulfated steroid. Indeed, a previous study proposed that the I307 residue plays a role in signal transduction between the transmitter binding sites and the channel gate or interacts with a sensor domain that translates steroid interaction with the receptor into a functional effect (Morris and Amin 2004) . Our data could also be accounted for by a model where potentiation and inhibition are mediated by two independent sites and mechanisms, and the nature of the ρ307 residue controls the balance between two opposing modulatory effects. In this model, any effect on ΔF may result from steroid interactions with one of the two sites, regardless of whether that interaction is productive with regard to function.
In sum, the data demonstrate the complexity of molecular mechanisms of how different inhibitory steroids act on the human ρ1 GABA A receptor. Despite a common macroscopic functional effect, we count at least four (5β-reduced steroids with methylketone at C17, 5β-reduced steroids without methylketone at C17, sulfated steroids, and 17β-estradiol) mechanisms when taking into consideration how selected mutations modulate inhibition and the structural changes that accompany the actions of steroids. We expect that future studies will refine the map of the GABA receptor channel to illustrate in greater detail the conformational changes taking place in the presence of modulators.
